StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Matinas BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$6.67M. For fiscal 2025 it was -$6.96M. The highest annual figure on record is -$3.71M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.96M–
FY2024Dec 31, 2024-$24.59M–
FY2023Dec 31, 2023-$23.77M–
FY2022Dec 31, 2022-$24.59M–
FY2021Dec 31, 2021-$24.74M–
FY2020Dec 31, 2020-$24.21M–
FY2019Dec 31, 2019-$18.92M–
FY2018Dec 31, 2018-$14.65M–
FY2017Dec 31, 2017-$16.50M–
FY2016Dec 31, 2016-$8.26M–
FY2015Dec 31, 2015-$9.91M–
FY2014Dec 31, 2014-$10.46M–
FY2013Dec 31, 2013-$3.71M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.56M–
Q1 FY2026Mar 31, 2026-$1.94M–
Q4 FY2025Dec 31, 2025-$1.60M–
Q3 FY2025Sep 30, 2025-$1.58M–
Q2 FY2025Jun 30, 2025-$1.84M–
Q1 FY2025Mar 31, 2025-$1.95M–
Q4 FY2024Dec 31, 2024-$8.47M–
Q3 FY2024Sep 30, 2024-$4.38M–
Q2 FY2024Jun 30, 2024-$5.84M–
Q1 FY2024Mar 31, 2024-$5.90M–
Q4 FY2023Dec 31, 2023-$5.89M–
Q3 FY2023Sep 30, 2023-$6.13M–
Q2 FY2023Jun 30, 2023-$6.16M–
Q1 FY2023Mar 31, 2023-$5.59M–
Q4 FY2022Dec 31, 2022-$5.48M–
Q3 FY2022Sep 30, 2022-$5.46M–
Q2 FY2022Jun 30, 2022-$5.93M–
Q1 FY2022Mar 31, 2022-$7.72M–
Q4 FY2021Dec 31, 2021-$6.71M–
Q3 FY2021Sep 30, 2021-$6.88M–
Q2 FY2021Jun 30, 2021-$4.79M–
Q1 FY2021Mar 31, 2021-$6.35M–
Q4 FY2020Dec 31, 2020-$6.49M–
Q3 FY2020Sep 30, 2020-$5.60M–
Q2 FY2020Jun 30, 2020-$5.77M–
Q1 FY2020Mar 31, 2020-$6.35M–
Q4 FY2019Dec 31, 2019-$5.74M–
Q3 FY2019Sep 30, 2019-$4.56M–
Q2 FY2019Jun 30, 2019-$4.52M–
Q1 FY2019Mar 31, 2019-$4.10M–
Q4 FY2018Dec 31, 2018-$4.17M–
Q3 FY2018Sep 30, 2018-$2.95M–
Q2 FY2018Jun 30, 2018-$3.40M–
Q1 FY2018Mar 31, 2018-$4.12M–
Q4 FY2017Dec 31, 2017-$4.63M–
Q3 FY2017Sep 30, 2017-$3.41M–
Q2 FY2017Jun 30, 2017-$3.98M–
Q1 FY2017Mar 31, 2017-$4.49M–
Q4 FY2016Dec 31, 2016-$2.56M–
Q3 FY2016Sep 30, 2016-$1.84M–

More Matinas BioPharma figures

See a number that looks wrong?